Compare Gilead Sciences, Inc. (GILD) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nuscale Power Corporation — how do they compare? Gilead Sciences, Inc. trades at $134.87 (market cap $163.51B), while Nuscale Power Corporation trades at $7.55 (market cap $2.89B). The key difference: Gilead Sciences, Inc. is far larger — about 56.6× Nuscale Power Corporation's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| GILD | SMR | |
|---|---|---|
Market Cap | $163.51B | $2.89B |
Sector | Health | Utilities |
52-Week High | $155.80 | $53.43 |
52-Week Low | $108.22 | $8.35 |
Enterprise Value | $178.05B | $2.00B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
NuScale Power (SMR) trades at $7.54, down 12.22% in the last session amid ongoing operational challenges. The stock shows bearish technical signals with key support at $7.00. Fundamentally, the company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with negative margins and cash burn from operations. Analyst consensus remains optimistic with a $12.25 price target despite recent earnings misses.
The investment case hinges on SMR's first-mover advantage in nuclear technology and potential AI-driven power demand, but faces significant execution risk. With no commercial reactors yet operational and substantial cash burn, the stock represents high-risk speculation. Current valuation appears stretched given negative profitability metrics and uncertain revenue timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
